open access

Vol 6, No 4 (2010)
Review paper
Published online: 2010-12-16
Get Citation

Cardiovascular complications in breast cancer patients — diagnostic aspects

Władysław Sinkiewicz, Joanna Banach
Onkol. Prak. Klin 2010;6(4):171-180.

open access

Vol 6, No 4 (2010)
REVIEW ARTICLES
Published online: 2010-12-16

Abstract

Recent progress in the modern oncology, with special regard to the early diagnosis and innovative, efficient anti-cancer treatment, prolonged lives and increased the number of completely recovered breast cancer patients. But yet, many of these treatments can cause cardiovascular injury such as cardiomyopathy, heart failure, myocardial ischaemia, arterial hypertension or thromboembolic events. Early diagnosis and the adequate reaction to such complications are a sine qua non conditions of successful treatment in this group of patients. The initial and periodic cardiologic assessment including anamnesis, physical examination and additional tests are indispensable elements of care of patients treated with potentially cardiotoxic agents. Echocardiography, ECG and biochemical markers determination are a considerable part of this diagnostic process. The essence of the appropriate care of breast cancer patients, especially those with preexisting cardiovascular risk factors and those treated with cardiotoxic drugs, is a perfectly organized cooperation between cardiologists and oncologists. In this article we review the current knowledge on chemotherapy-related cardiovascular injury, its incidence, plausible mechanisms and the diagnostic techniques with special attention to biochemical markers and models of cardiooncology team-work.

Onkol. Prak. Klin. 2010; 6, 4: 171–180

Abstract

Recent progress in the modern oncology, with special regard to the early diagnosis and innovative, efficient anti-cancer treatment, prolonged lives and increased the number of completely recovered breast cancer patients. But yet, many of these treatments can cause cardiovascular injury such as cardiomyopathy, heart failure, myocardial ischaemia, arterial hypertension or thromboembolic events. Early diagnosis and the adequate reaction to such complications are a sine qua non conditions of successful treatment in this group of patients. The initial and periodic cardiologic assessment including anamnesis, physical examination and additional tests are indispensable elements of care of patients treated with potentially cardiotoxic agents. Echocardiography, ECG and biochemical markers determination are a considerable part of this diagnostic process. The essence of the appropriate care of breast cancer patients, especially those with preexisting cardiovascular risk factors and those treated with cardiotoxic drugs, is a perfectly organized cooperation between cardiologists and oncologists. In this article we review the current knowledge on chemotherapy-related cardiovascular injury, its incidence, plausible mechanisms and the diagnostic techniques with special attention to biochemical markers and models of cardiooncology team-work.

Onkol. Prak. Klin. 2010; 6, 4: 171–180

Get Citation

Keywords

cardiotoxicity; biochemical markers; cardiooncology

About this article
Title

Cardiovascular complications in breast cancer patients — diagnostic aspects

Journal

Oncology in Clinical Practice

Issue

Vol 6, No 4 (2010)

Article type

Review paper

Pages

171-180

Published online

2010-12-16

Bibliographic record

Onkol. Prak. Klin 2010;6(4):171-180.

Keywords

cardiotoxicity
biochemical markers
cardiooncology

Authors

Władysław Sinkiewicz
Joanna Banach

References (29)
  1. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006; 113(6): 791–798.
  2. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol. 2007; 25(31): 4952–4960.
  3. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009; 53(24): 2231–2247.
  4. Wouters KA, Kremer LCM, Miller TL, et al. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005; 131(5): 561–578.
  5. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf. 2000; 22(4): 263–302.
  6. Goldberg MA, Antin JH, Guinan EC, et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986; 68(5): 1114–1118.
  7. Morandi P, Ruffini PA, Benvenuto GM, et al. Cardiac toxicity of high-dose chemotherapy. Bone Marrow Transplant. 2005; 35(4): 323–334.
  8. Chen MH, Kerkelä R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008; 118(1): 84–95.
  9. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med. 2002; 8(5): 459–465.
  10. de Forni M, Malet-Martino MC, Jaillais P, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol. 1992; 10(11): 1795–1801.
  11. Jensen SA, Sørensen JB, Jensen SA, et al. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol. 2006; 58(4): 487–493.
  12. Robben NC, Pippas AW, Moore JO. The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer. 1993; 71(2): 493–509.
  13. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008; 134(1): 75–82.
  14. Frickhofen N, Beck FJ, Jung B, et al. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol. 2002; 13(5): 797–801.
  15. Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991; 9(9): 1704–1712.
  16. Jones LW, Haykowsky MJ, Swartz JJ, et al. Early breast cancer therapy and cardiovascular injury. J Am Coll Cardiol. 2007; 50(15): 1435–1441.
  17. Popat S, Smith IE. Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects. Nat Clin Pract Oncol. 2008; 5(6): 324–335.
  18. Cardinale D, Sandri MT, Martinoni A, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002; 13(5): 710–715.
  19. Sandri MT, Cardinale D, Zorzino L, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem. 2003; 49(2): 248–252.
  20. Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004; 109(22): 2749–2754.
  21. Dolci A, Dominici R, Cardinale D, et al. Biochemical Markers for Prediction of Chemotherapy-Induced Cardiotoxicity. American Journal of Clinical Pathology. 2008; 130(5): 688–695.
  22. Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010; 28(25): 3910–3916.
  23. Meinardi MT, van Veldhuisen DJ, Gietema JA, et al. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients. J Clin Oncol. 2001; 19(10): 2746–2753.
  24. Ekstein S, Nir A, Rein AJ, et al. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children. J Pediatr Hematol Oncol. 2007; 29(7): 440–444.
  25. Horacek JM, Pudil R, Jebavy L, et al. Assessment of anthracycline-induced cardiotoxicity with biochemical markers. Exp Oncol. 2007; 29(4): 309–313.
  26. Cil T, Kaplan AM, Altintas A, et al. Use of N-terminal pro-brain natriuretic peptide to assess left ventricular function after adjuvant doxorubicin therapy in early breast cancer patients: a prospective series. Clin Drug Investig. 2009; 29(2): 131–137.
  27. Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. 2005; 51(8): 1405–1410.
  28. Chen S, Garami M, Gardner DG. Doxorubicin selectively inhibits brain versus atrial natriuretic peptide gene expression in cultured neonatal rat myocytes. Hypertension. 1999; 34(6): 1223–1231.
  29. Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010; 102(1): 14–25.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl